Sedana Medical AB (SE:SEDANA)
:SEDANA
Top Page
Sedana Medical AB
(SEDANA)
Select Model
Select Model
Rating:44Neutral
Price Target:
kr8.50
▼(-20.71% Downside)
Action:ReiteratedDate:02/18/26
The score is held down primarily by ongoing losses and negative operating/free cash flow, despite strong revenue growth and a very low-leverage balance sheet. Technicals show a weaker longer-term trend with neutral near-term momentum, and valuation is constrained by loss-making earnings and no dividend support.
Positive Factors
Revenue Growth & Gross Margins
Consistent multi-year revenue growth combined with ~71% gross margins indicates strong unit economics and product pricing power. Durable top-line expansion plus high gross margin supports reinvestment in commercialization and R&D and creates a realistic pathway to profitability if operating leverage improves.
Negative Factors
Negative Cash Generation
Persistent negative operating and free cash flow means the business relies on external funding to sustain operations and commercialization. Although FCF burn improved in 2025, continued cash consumption increases financing risk, can dilute shareholders, and constrains autonomous investment capacity over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth & Gross Margins
Consistent multi-year revenue growth combined with ~71% gross margins indicates strong unit economics and product pricing power. Durable top-line expansion plus high gross margin supports reinvestment in commercialization and R&D and creates a realistic pathway to profitability if operating leverage improves.
Read all positive factors
Sedana Medical AB (SEDANA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr876.15M
Dividend YieldN/A
Average Volume (3M)247.68K
Price to Earnings (P/E)―
Beta (1Y)0.92
Revenue Growth13.48%
EPS Growth28.98%
CountrySE
Employees113
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.10
Shares Outstanding99,336,960
10 Day Avg. Volume186,290
30 Day Avg. Volume247,675
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.13
Price to Sales (P/S)5.10
P/FCF Ratio-13.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.23
Revenue Forecast (FY)kr217.50M
Sedana Medical AB Business Overview & Revenue Model
Company Description
Sedana Medical AB (publ), a medical technology company, develops, markets, and sells medical devices in Sweden and internationally. The company offers Sedaconda ACD-L and Sedaconda ACD-, which are disposable medical devices that enables the admini...
How the Company Makes Money
Sedana Medical generates revenue primarily by selling consumable ICU sedation products tied to the use of inhaled anesthetics in ventilated patients. A core revenue stream is the sale of its Sedaconda ACD devices (disposable/consumable components ...
Sedana Medical AB Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
78
Positive
Cash Flow
27
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 200.23M | 178.75M | 153.87M | 122.86M | 159.15M |
| Gross Profit | 142.71M | 126.14M | 108.98M | 86.07M | 106.71M |
| EBITDA | -10.12M | -4.03M | -51.67M | -64.87M | -49.10M |
| Net Income | -59.24M | -10.67M | -59.61M | -73.51M | -57.97M |
Balance Sheet | |||||
| Total Assets | 954.46M | 1.02B | 1.01B | 1.08B | 1.17B |
| Cash, Cash Equivalents and Short-Term Investments | 90.98M | 193.96M | 381.80M | 607.74M | 836.18M |
| Total Debt | 4.70M | 5.92M | 4.31M | 8.74M | 8.87M |
| Total Liabilities | 53.68M | 61.17M | 44.06M | 52.43M | 66.12M |
| Stockholders Equity | 900.78M | 958.23M | 970.00M | 1.03B | 1.10B |
Cash Flow | |||||
| Free Cash Flow | -75.19M | -186.77M | -206.95M | -253.22M | -151.48M |
| Operating Cash Flow | -12.78M | -11.77M | -38.06M | -115.43M | -41.22M |
| Investing Cash Flow | -63.03M | -44.67M | -321.96M | -137.78M | -110.25M |
| Financing Cash Flow | -4.04M | -3.57M | -4.86M | -1.51M | 605.07M |
Sedana Medical AB Technical Analysis
Negative
10.72
Price Trends
9.40
Negative
9.73
Negative
11.49
Negative
Market Momentum
-0.13
Negative
46.19
Neutral
61.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SEDANA, the sentiment is Negative. The current price of 10.72 is above the 20-day moving average (MA) of 8.94, above the 50-day MA of 9.40, and below the 200-day MA of 11.49, indicating a bearish trend. The MACD of -0.13 indicates Negative momentum. The RSI at 46.19 is Neutral, neither overbought nor oversold. The STOCH value of 61.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SEDANA.
Sedana Medical AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | kr1.08B | -74.03 | -4.20% | ― | 21.71% | -80.37% | |
55 Neutral | kr894.82M | 103.06 | 6.93% | ― | -5.80% | -65.99% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr654.01M | -5.78 | -36.55% | ― | 62.24% | 21.16% | |
47 Neutral | kr699.16M | -24.57 | ― | ― | 38.43% | 57.76% | |
44 Neutral | kr876.15M | -17.24 | -4.42% | ― | 13.48% | 28.98% | |
42 Neutral | kr185.88M | -5.27 | -18.55% | ― | 0.62% | -82.70% |
* Healthcare Sector Average
SE:SEDANA
Sedana Medical AB
8.82
1.94
28.20%
SE:PAX
Paxman AB
46.50
-18.10
-28.02%
SE:SEZI
Senzime AB
4.16
-0.04
-0.83%
SE:CRAD.B
C-Rad AB Class B
26.50
0.15
0.57%
SE:INTEG.B
Integrum AB Class B
6.97
-7.58
-52.11%
SE:OSSD
OssDsign AB
6.32
-4.64
-42.34%
Sedana Medical AB Corporate Events
Sedana Medical Treats First U.S. Patient in FDA-Approved Early Access Sedation Program
Mar 13, 2026
Sedana Medical has treated the first U.S. patient under its FDA‑approved Early Access Program, giving critically ill “difficult‑to‑sedate” intensive care patients access to its investigational inhaled isoflurane‑...
Sedana Medical Narrows Losses and Turns Ex-US EBITDA Positive Amid 2025 Sales Growth
Feb 12, 2026
Sedana Medical reported 5% year-on-year net sales growth in the fourth quarter of 2025 to SEK 51.8 million, or 11% at constant exchange rates, with gross margin improving to 73%. EBITDA turned slightly positive at group level and reached an 8% mar...
Sedana Medical Schedules Q4 2025 Interim Report Release and Investor Presentation
Jan 29, 2026
Sedana Medical AB will publish its interim report for the fourth quarter of 2025 on 12 February 2026 at around 07:00 CET and will present the results later the same day at 13:30 CET via an audiocast and teleconference. The presentation, led by CEO...
Sedana Medical Strengthens Leadership with New CFO Ahead of US Expansion
Jan 27, 2026
Sedana Medical has appointed experienced finance executive Mikael Haag as its new Chief Financial Officer and member of the Executive Management Team, with him set to assume the role no later than July 2026, while current CFO Johan Spetz will stay...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.